In8bio, Inc. insider trading

Every open-market purchase and sale by In8bio, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

No open-market insider trades reported in the last five years.

Does following In8bio, Inc.’s insiders pay?

From August 17, 2022 to August 28, 2023, 13 insiders reported 15 open-market purchases and 0 sales not made under a pre-set plan in In8bio, Inc.

In8bio, Inc.: each insider's record
Insider	Role	Purchases	12 months after their purchases	Beat the S&P 500	12 months after their sales	Latest report
Bios Fund II Nt, LP	Director	2	—	—	—	September 29, 2022
Ho William Tai-Wei	President and CEO	2	—	—	—	August 28, 2023
Bios Advisors Gp, LLC	Director	1	—	—	—	August 17, 2022
Bios Equity Partners II, LP	Director	1	—	—	—	September 29, 2022
Bios Fund II Qp, LP	Director	1	—	—	—	August 30, 2022
Bios Fund II, LP	Director	1	—	—	—	August 17, 2022
Bios Fund III Qp, LP	Director	1	—	—	—	December 13, 2022
Brandt Peter C.	Director	1	—	—	—	August 18, 2022
Cavu Advisors, LLC	Director	1	—	—	—	August 30, 2022
Cavu Management, LP	Director	1	—	—	—	August 18, 2022
Kreis Leslie W.	Director	1	—	—	—	December 13, 2022
Roemer Alan S.	Director	1	—	—	—	August 18, 2022
Transcend Partners Opportunity Fund LLC	Director	1	—	—	—	August 18, 2022

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

← Back to In8bio, Inc. · Funds · Politicians